Coesia Financing

Coesia S.p.A., the Bologna-based industrial group controlled by the Seragnoli family, has assembled one of the most technically sophisticated packaging machinery portfolios in the world. The group's brands include G.D (cigarette and tobacco processing machinery), IMA (pharmaceutical and cosmetic packaging), Volpak (horizontal pouch and sachet machines), Neyret (high-speed flexible packaging), and others. The common thread across those brands is engineering precision at high line speeds, and that engineering quality is exactly why Coesia equipment carries significant capital cost and holds value well over a long service life.

Financing Coesia equipment means understanding that the relevant brand within the Coesia portfolio determines a lot about the transaction. An IMA pharmaceutical packaging line for oral solid dosage products has a different regulatory context, validation requirement, and secondary-market profile than a Volpak horizontal pouch machine for food or personal care applications. A G.D tobacco processing line operates in a highly regulated, highly specialized segment with its own lender considerations. We handle all of these transaction types and match each to the appropriate lender rather than applying a uniform approach across the Coesia portfolio.

The minimum transaction size we work with is $50,000. Most individual Coesia brand machines exceed that floor materially because the engineering at this tier of the market commands a corresponding price. For transactions up to approximately $400,000 we can often move on an application-only basis. Above that threshold, a standard credit review applies. Funding typically completes within one to two weeks of a clean application. For complete line projects with phased delivery, we structure milestone disbursements aligned with manufacturing and installation progress.

Coesia Brand Equipment We Finance

IMA Group equipment is the most common Coesia transaction in our pharmaceutical and nutraceutical financing work. IMA produces filling machines, cartoners, blistering lines, capsule filling systems, and complete oral solid dosage packaging lines. These machines are deployed heavily by pharmaceutical manufacturers, contract drug manufacturers, and nutraceutical producers globally. The capital cost of a serious IMA blistering or cartoning line is substantial, and the validation requirements in pharma environments mean the total project cost including IQ/OQ/PQ qualification can be multiples of the equipment cost alone.

We work with Pharmaceutical Manufacturing and Nutraceutical & Supplement Manufacturing on IMA equipment financing regularly. The pharma segment's familiarity with complex capital projects and regulatory timelines means these clients are generally well-prepared for the financing documentation process, and we in turn are prepared for the specific documentation needs of pharma equipment projects. Validation costs can sometimes be included in the facility as soft costs, depending on the lender and the scope.

Volpak horizontal pouch and sachet equipment addresses food, personal care, and pharmaceutical sachet applications. A Volpak horizontal machine for single-serve condiment packets, nutritional supplement sachets, or cosmetic sample packets is a highly specialized asset with a focused buyer market. We finance new Volpak systems and used Volpak equipment that appears on the secondary market through plant closures or format rationalization.

G.D tobacco and cigarette processing machinery is a specialized segment. G.D is the global market leader in cigarette manufacturing equipment, and financing G.D assets requires lender familiarity with the tobacco industry's financial and regulatory structure. We work with lenders who operate in the tobacco segment and who understand the specific considerations that apply to tobacco processing equipment as collateral.

For complete Coesia group line configurations that combine IMA pharmaceutical packaging with other Coesia group components, or that integrate Coesia equipment with Packaging Line Financing from other OEMs, we structure omnibus facilities covering the full project. That is particularly relevant in pharmaceutical environments where the complete line, not individual machines, is the unit of validation.

The Financing Path for Coesia Equipment

The application process for Coesia equipment financing follows the same sequence as our other packaging machinery work, but with adjustments for the specific context of each Coesia brand. For IMA pharma equipment, we request information about the regulatory environment, the validation timeline, and the production context (new drug, existing validated format, NDA expansion, etc.) because those details shape how the lender evaluates the deal. For Volpak food-grade equipment, the context is more straightforward and the documentation burden is lighter.

New Coesia equipment ordered directly from the relevant brand entity typically carries lead times that range from several months to over a year for complex pharmaceutical lines. We issue financing commitments at approval, before the factory order is placed, so the purchase process does not stall while loan documents are prepared. The disbursement happens at delivery or in milestone stages for large multi-component orders.

Used Coesia equipment, particularly IMA pharmaceutical machinery, requires attention to the machine's qualification history. A validated IMA capsule filler or blister packer that was decommissioned following a manufacturing site change carries different value than one that was retired for mechanical reasons. Lenders familiar with pharma equipment understand the distinction, and we make sure the right context is presented with the asset description.

B and C credit situations are evaluated based on the full picture. Strong IMA or Volpak collateral, a history of production in the relevant segment, and customer contracts or regulatory approvals that provide revenue context all contribute to a funding decision that may not reflect what a credit score alone would suggest. We present these situations to lenders who specialize in the relevant equipment category and who can evaluate the deal on its merits.

Related Financing Structures for Coesia Equipment

Sale-leaseback is a particularly relevant structure for Coesia pharma equipment because validated machines that sit near zero on the balance sheet may still command meaningful secondary-market value. An IMA line that a pharmaceutical company has validated and operated for several years is genuinely scarce on the market for buyers who need that specific validated format, and that scarcity is reflected in appraisal value. Converting that value to cash through a Sale-Leaseback is a rational use of equipment equity in the context of an ongoing pharmaceutical operation.

For Coesia equipment acquisitions where the buyer is a pharmaceutical contract manufacturer adding capacity for a new customer contract, the production-linked payment logic of an operating lease can align with the revenue timeline better than a conventional loan. Lease structures where the payment reflects the production economics of the new line are worth exploring at the structuring stage.

Equipment refinancing is available for Coesia assets carrying existing loan balances. If the equipment has appreciated (as validated pharma equipment sometimes does when the OEM no longer produces the exact configuration), or if the original loan rate was set in a different market environment, a refinance can produce meaningful improvement in terms.

For operators funding a complete Coesia project that also includes upstream processing equipment, conveyors, or material handling, linking the Coesia component to a broader Production Line Upgrade Financing structure keeps the full project under one facility. That approach avoids the complexity of coordinating multiple lenders and multiple closing timelines on a project where all the components are interdependent.

Finance Your Coesia Equipment

Tell us which Coesia brand and equipment you are acquiring, the project value, and the regulatory context if pharma. We will structure a facility that fits both the asset and the operating environment. Minimum $50,000.